Freshfields has advised Asahi Kasei Group subsidiary Veloxis Pharmaceuticals on the acquisition of AiCuris Anti-infective Cures for approximately EUR 780 million.
According to Freshfields, AiCuris is a pharmaceutical company focused on drug candidates for the prevention and treatment of severe infectious diseases.
The Freshfields team included Vienna-based Partner Stephan Denk, Counsel Lukas Pomaroli, and Associate Julia Sommer, with further lawyers in Berlin, Frankfurt, Hamburg, Duesseldorf, and New York.
Freshfields did not respond to our inquiry on the matter.
